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Intratumor heterogeneity implies heterogeneous protein function, facilitating tumor adaptation which results in
therapeutic failure.We hypothesized that tumor heterogeneity at protein levelmay influence the course of the disease.
As a single biopsy might not represent the full biologic complexity of the tumor, we have analyzed
immunohistochemically four different cores obtained from each primary tumor within the cohort of 364 patients
with endometrial cancer (EC). The following proteins were examined: estrogen receptor 1 (ESR1), progesterone
receptor, epidermal growth factor receptor, v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, receptor
tyrosine-protein kinase erbB-3, v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 4, phosphatidylinositol-
4,5-bisphosphate 3-kinase, phosphorylated v-akt murine thymoma viral oncogene homolog 1, v-myc avian
myelocytomatosis viral oncogene homolog, DNA topoisomerase II alpha 170 kDa (TOP2A), cyclin-dependent kinase
inhibitor 2A (CDKN2A), tumor protein p53, RAD21 homolog, S. pombe, and runt-related transcription factor 1.
Particularly strong correlation was found between TOP2A and CDKN2A heterogeneity and higher stage of the disease
(P = .0002 and P = .0003, respectively). Most correlations with clinicopathologic data were observed for ESR1
heterogeneity that correlated with non-endometrioid carcinomas (P=.02), higher stage (P=.005), grade (P=.01), and
the presence of metastases (P = .01). Thirty-nine (11.0%) patients were classified as “globally heterogeneous”.
Cumulative tumor heterogeneity strongly correlated with the presence of metastases, higher stage, and higher grade
of the disease (all P b .05). It also carried negative prognostic value (P=.0008). We show that the degree of
heterogeneity in EC might serve as a clinically valid molecular marker.
Translational Oncology (2014) 7, 613–619carried out the experiments. A.S. and A.J.Z. analyzed the data. All authors were
involved in writing the paper and had final approval of the submitted and
published versions.
Received 14 May 2014; Revised 19 June 2014; Accepted 23 June 2014
© 2014 The Authors. Published by Elsevier Inc. on behalf of Neoplasia Press, Inc. This
is an open access article under the CC BY-NC-ND license (http://creativecommons.
org/licenses/by-nc-nd/3.0/).
1936-5233/14
http://dx.doi.org/10.1016/j.tranon.2014.06.001
Table 1. EC Patients' Characteristics (N = 364)
Variable Number of Cases (%)
Menopausal status
Premenopausal 27 (7.4%)
Perimenopausal 22 (6.0%)
Postmenopausal 314 (86.3%)
Missing data 1 (0.3%)
Age
≤50 years 39 (10.7%)
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Endometrial cancer (EC) is the most frequent malignancy of the
female genital tract in the Western world, with approximately 90,000
new cases registered each year in the European Union [1]. Despite the
high prevalence, the understanding of the molecular background of EC
with regard to its pathogenesis and disease progression remains
insufficient. Data concerning tumor heterogeneity in EC are especially
scarce. Recent discoveries have shown that tumor composition is
heterogeneous and consists of various cell clones. This intratumor
heterogeneity depends on heterogeneous protein function, which can
facilitate tumor adaptation, resulting in therapeutic failure through
Darwinian selection [2]. Furthermore, intratumor heterogeneity was
detected in all types of studied cancers [3,4] and may lead to more
aggressive tumor behavior and unfavorable outcome [5,6].
As a single biopsy might not represent the full biologic complexity
of the tumor, we used immunohistochemistry (IHC) to analyze four
different cores obtained from each primary tumor within the cohort
of patients with EC. Tumor heterogeneity might affect the response
to treatment. Thus, the study included the expression analysis of the
proteins often related to target therapies. The following proteins were
examined: estrogen receptor 1 (ESR1), progesterone receptor (PGR),
epidermal growth factor receptor (ERBB1), v-erb-b2 erythroblastic
leukemia viral oncogene homolog 2(ERBB2, also known as HER2),
receptor tyrosine-protein kinase erbB-3 (ERBB3), v-erb-b2 avian
erythroblastic leukemia viral oncogene homolog 4 (ERBB4),
phosphatidylinositol-4,5-bisphosphate 3-kinase (PIK3CA), phosphorylated
v-akt murine thymoma viral oncogene homolog 1 (pAKT1), v-myc avian
myelocytomatosis viral oncogene homolog (MYC), DNA topoisomer-
ase II alpha, 170 kDa (TOP2A), cyclin-dependent kinase inhibitor 2A
(CDKN2A, also known as p16), tumor protein p53 (TP53), RAD21
(RAD21 homolog, S. pombe), and runt-related transcription factor 1
(RUNX1).We hypothesized that the existence of cellular heterogeneity
within the tumor, identified in four different cores (analyzed by IHC)
belonging to the same patient, may influence the course of the disease
and affect patients’ survival.N50 years 325 (89.3%)
Obesity
Absent 173 (47.5%)
Present 190 (52.2%)
Missing data 1 (0.3%)
Histology
Endometrioid 332 (91.2%)
Non-endometrioid 27 (7.4%)
Missing data 5 (1.4%)
Stage (FIGO)
IA-IB 246 (67.6%)
II 53 (14.6%)
IIIA-IIIC 44 (12.1%)
IVA-IVB 16 (4.4%)
Missing data 5 (1.4%)
Grade
I 173 (47.5%)
II 134 (36.8%)
III 47 (12.9%)
Missing data 10 (2.7%)
Cervical invasion
Absent 268 (73.6%)
Present 91 (25.0%)
Missing data 5 (1.4%)
Myometrial infiltration
≤1/2 168 (46.2%)
N1/2 191 (52.3%)
Missing data 5 (1.4%)
Metastases
Absent 321 (88.2%)
Present 34 (9.3%)
Missing data 9 (2.5%)Patients and Methods
Patients and Tissues
The study included 364 formalin-fixed paraffin-embedded (FFPE)
primary tumor samples retrospectively collected from a cohort of EC
patients who were operated in the Department of Gynaecology,
Gynaecological Oncology and Gynaecological Endocrinology,
Medical University of Gdańsk (Gdańsk, Poland) between 2000
and 2010. Each patient was primarily treated by surgery, with the
possible option of radiotherapy and/or chemotherapy administration.
The inclusion criteria were operable EC (stage IVB patients underwent
cytoreductive surgery) confirmed by histologic examination and a
signed consent form.The study was accepted by the Independent Ethics
Committee of the Medical University of Gdańsk (NKEBN/269/2009,
date: 14 September 2009). Procedures involving human subjects were
in accordancewith theHelsinkiDeclaration of 1975, as revised in 1983.
The tumor samples included all stages of endometrial carcinoma,
from stage IA to IVB, as distinguished by the International Federation
of Gynecology and Obstetrics (FIGO) in 2009 [7]. We analyzed
all primary carcinomas of the uterine corpus, separating them into
endometrioid and non-endometrioid tumors. The latter included
serous, clear cell, mucinous, mixed, squamous cell, and undifferentiated
carcinomas [8]. Metastases included lymph node and distantmetastases. The patients’ characteristics are summarized in Table 1.
The median age was 63 (range, 26-89 years). Patients with a body mass
index higher than 30 were classified as obese [9]. A survival analysis was
performed for 362 (99.5%) patients. After a median follow-up of 72.5
months (range, 0-158), 107 (29.4%) patients had died. The last follow-
up data were collected in September 2013. The study was performed in
accordance with the REcommendations for Tumor MARKer Prog-
nostic Studies (REMARK) criteria [10].
IHC on Tissue Microarrays
Samples were collected by surgical excision before any systemic
treatment and were fixed in 10% (vol/vol) neutral buffered formalin
for up to 24 hours, dehydrated in 70% ethanol, and embedded in
paraffin. FFPE tissue blocks were stored at room temperature for up
to 14 years. The percentage of tumor cells in each FFPE specimen was
evaluated by hematoxylin and eosin staining reviewed by a certified
pathologist. Tissue microarrays (TMAs) were constructed from
FFPE surgical resection tumor specimens and control samples. Four
1.5-mm-diameter cores from each tumor were obtained from the
most representative areas (well-preserved fragments of invasive
carcinoma, without necrosis, autolysis, and squamous metaplasia)
using a tissue-arraying instrument (MTA-I; Beecher Instruments,
Sun Prairie, WI), and then reembedded in microarray blocks.
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in internal controls to the system. Consecutive 4-μm-thick TMA
sections were cut and placed on charged polylysine-coated slides
(Superfrost Plus; BDH, Braunschweig, Germany) for subsequent
IHC analysis.
Protein expression was examined by IHC on TMA blocks using the
following antibodies: ESR1 – clone SP1 (Roche, Basel, Switzerland),
PGR – clone 1E2 (Roche), ERBB1 – clone EGFR113 (Novocastra,
Wetzlar, Germany), ERBB2 – clone 4B5 (Roche), ERBB3 – cloneDAK-
H3-IC (DAKO, Glostrup, Denmark), ERBB4 – clone HFR1 (Abcam,
Cambridge, United Kingdom), PIK3CA – clone C73F8 (Cell Signaling
Technology, Danvers, MA), pAKT1 – clone D9E (Cell Signaling
Technology), MYC – clone 9E11 (Novocastra), TOP2A – clone Ki-S1
(DAKO), CDKN2A – clone JC8 (Santa Cruz Biotechnology, Dallas,
TX), TP53 – clone BP-53-11 (Roche), RAD21 – polyclonal antibody
(Abcam), and RUNX1 – clone DW71 (Santa Cruz Biotechnology). The
staining has been performed in accordance with the manufacturers’
guidelines; details are presented as Supplementary Materials (Table W1).
Protein expression evaluation was performed by two pathologists
(H.M. and J.G.) blinded to clinical data. ESR1 and PGR evaluation
of the nuclear staining was performed on the basis of Allred score
[11]. ERBB2 receptor status was determined on the basis of the
criteria of HercepTest (DAKO) according to the manufacturer’s
guidelines, as previously described [12,13]. The interpretation criteria
for the remaining proteins were based on the intensity of the staining
and the percentage of cells showing positive reaction (0-100%),
which gave the final staining score, as the result of either sum or
multiplication, dependent on reported criteria for a particular protein
[14–20]. Data published on The Human Protein Atlas were also
taken into account (http://www.proteinatlas.org/, last accessed: 16
June 2014). Cutoff point determination of expression positivity,
based on result distribution, was performed with the use of Cutoff
Finder Web Application [21]. Cutoff point determination of the
tumor heterogeneity, understood as different staining intensities
between the cores belonging to the same patient, was performed
individually for each protein as the proteins differed in staining
characteristics. Details are presented as Supplementary Materials
(Table W2). For tumor heterogeneity evaluation, staining determi-
nation of at least three cores was required. As an example, ESR1 and
TOP2A tumor heterogeneity is presented in the four cores taken from
the same primary tumor sample (Figures W1 and W2). Additionally,
cumulative heterogeneity was determined for each patient, based on
nine proteins that correlated with clinicopathologic characteristics
and/or survival (ESR1, PGR, PIK3CA, pAKT1, MYC, TOP2A,
CDKN2A, RAD21, and RUNX1). For each patient, a score between
0 and 9was obtained (1 point for each protein classified as heterogeneous,
according to the criteria described inTableW2).On the basis of the resultFigure 1. Graphical representadistribution, primary tumors with a score of at least 3 were classified as
“globally” heterogeneous.
Statistical Analysis
STATISTICA software (version 10; StatSoft Co, Tulsa, OK) was
used for all calculations. The tests that were used and their
applications were given as follows: testing normality of the data
set— Shapiro-Wilk test; comparison of the tumor heterogeneity with
clinicopathologic data of the patients – crosstabs statistics with
Pearson Chi-square test; correlations between the heterogeneity of the
studied proteins – crosstabs statistics with Pearson Chi-square test.
The Kaplan-Meier estimator was employed for survival analysis, and
the generated curves were compared with the log-rank test. The
endpoint for the study was overall survival (OS). OS was defined as
the time from sample collection to death or censoring. Censoring was
defined as loss of follow-up or alive at the end of follow-up. Statistical
significance was assumed when P ≤ .05. Cox proportional hazards
regression analysis was used to identify the independent predictors of
OS. Univariate predictors that are significant with a value of P ≤ .10
were entered into a step-wise multivariate model to identify those
with independent prognostic information.
Results
Flow of Samples
For tumor heterogeneity evaluation, staining determination of at
least three cores was required. Within the group of 364 patients,
tumor heterogeneity was assessed for 310 to 355 (85.2-97.5%) cases,
depending on the staining success of a given protein (Table W2).
Global heterogeneity was assessed for 355 patients, as cases with less
than five assessed proteins were not considered in the context of
global heterogeneity due to the lack of significant proportion of data.
Graphical representation of tumor heterogeneity within this group is
presented in Figure 1.
Correlation of Tumor Heterogeneity with Clinical and
Pathologic Data
Tumor heterogeneity of the studied proteins was compared with
tumor histology, grade, and stage as well as the presence of
metastases (Table 2). Parameters such as menopausal status, age,
obesity, or myometrial infiltration were not included in the table as
these analyses yielded statistically insignificant results. Particularly
strong correlation was found between TOP2A and CDKN2A
heterogeneity and higher stage of the disease (P = .0002 and
P = .0003, respectively).Most correlations with clinicopathologic data
were observed for ESR1 heterogeneity that correlated with non-
endometrioid tumors (P = .02), higher stage (P = .005), grade (P = .01),
and the presence ofmetastases (P = .00001).No correlations were foundtion of tumor heterogeneity.
Table 2. Patients Classified as Protein Heterogeneous in the Context of Clinicopathologic Data
PIK3CA MYC TOP2A ESR1
Number of
Heterogeneous Samples
P Value Number of
Heterogeneous Samples
P Value Number of
Heterogeneous Samples
P Value Number of
Heterogeneous Samples
P Value
Histology Endometrioid 70/323 (21.7%) .28 51/298 (17.1%) .38 28/286 (9.8%) .21 24/320 (7.5%) .02
Non-endometrioid 8/26 (30.8%) 6/25 (24.0%) 4/22 (18.2%) 5/24 (20.8%)
Stage I, II 58/289 (20.1%) .01 45/266 (16.9%) .29 19/255 (7.5%) .0002 14/238 (5.9%) .005
III, IV 21/60 (35.0%) 13/57 (22.8%) 13/52 (25.0%) 15/108 (13.9%)
Grade 1, 2 64/298 (21.5%) .15 42/274 (15.3%) .002 24/260 (9.2%) .14 21/295 (7.2%) .01
3 14/45 (31.1%) 15/43 (34.9%) 7/42 (16.7%) 8/43 (18.6%)
Metastases Absent 65/311 (20.9%) .02 49/288 (17.0%) .10 25/275 (9.1%) .02 20/308 (6.5%) .01
Present 13/34 (38.2%) 9/31 (29.0%) 7/30 (23.3%) 6/31 (19.4%)
PGR RUNX1 RAD21 CDKN2A
Number of
Heterogeneous Samples
P Value Number of
Heterogeneous Samples
P Value Number of
Heterogeneous Samples
P Value Number of
Heterogeneous Samples
P Value
Histology Endometrioid 52/318 (16.4%) .20 16/283 (5.7%) .79 17/296 (5.7%) .18 23/319 (7.2%) .03
Non-endometrioid 7/27 (25.9%) 1/23 (4.4%) 3/24 (12.5%) 5/26 (19.2%)
Stage I, II 48/286 (16.8%) .33 10/252 (4.0%) .002 13/268 (4.9%) .005 17/285 (6.0%) .0003
III, IV 13/59 (22.0%) 8/53 (15.1%) 8/52 (15.4%) 12/59 (20.3%)
Grade 1, 2 46/297 (15.5%) .004 14/258 (5.4%) .66 17/270 (6.3"%) .92 20/296 (6.8%) .001
3 14/42 (33.3%) 3/42 (7.1%) 3/45 (6.7%) 9/42 (21.4%)
Metastases Absent 52/308 (16.9%) .14 13/274 (4.7%) .005 14/290 (4.8%) .00004 20/307 (6.5%) .0004
Present 9/33 (27.3%) 5/28 (17.9%) 7/28 (25.0%) 8/33 (24.2%)
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the tumor heterogeneity of ERBB1, ERBB2, ERBB3, ERBB4, pAKT1,
and TP53, thus these proteins were included in Table W3 only.
Correlations between the Heterogeneity of the Studied Proteins
Tumor heterogeneity of the studied proteins was compared
with each other. Strong correlation was found between ESR1 and
PGR heterogeneity (r = 0.30, P = .000002), ESR1 and RAD21
heterogeneity (r = 0.23, P = .0003), and pAKT1 and ERBB1
heterogeneity (r = 0.24, P = .0002).
Survival Analysis
Protein heterogeneity of MYC, TOP2A, ESR1, and RAD21
correlated with shortened OS. The same trend was observed for
ERBB4, RUNX1, and CDKN2A. No prognostic impact was
detected for ERBB1, ERBB2, ERBB3, PIK3CA, pAKT1, PGR,
and TP53 tumor heterogeneity (Table 3). Staining intensity was also
analyzed in the context of prognosis. Low ESR1, PGR, and ERBB3Table 3. Univariate Analysis of Protein Tumor Heterogeneity as Prognostic Factors in EC
Status of the Analyzed Protein
(Heterogeneous vs Non-heterogeneous)
Univariate Analysis
HR 95% CI P Value
ERBB1 0.51 0.16-1.61 .25
ERBB2 1.36 0.80-2.32 .25
ERBB3 0.76 0.51-1.13 .17
ERBB4 1.42 0.96-2.10 .08
PIK3CA 1.11 0.70-1.75 .65
MYC 1.7 1.08-2.70 .02
pAKT1 1.31 0.78-2.20 .31
TOP2A 2.11 1.24-3.60 .006
ESR1 1.89 1.06-3.34 .03
PGR 1.42 0.88-2.30 .15
RUNX1 1.99 0.99-4.00 .05
RAD21 2.23 1.17-4.23 .01
CDKN2A 1.75 0.97-3.16 .06
TP53 1.11 0.66-1.86 .70
Note: HR, hazard ratio; CI, confidence interval.expression as well as high ERBB2, TOP2A, and TP53 expression
correlated with shorter OS (Table W4).
Cumulative Tumor Heterogeneity
As hierarchical clustering of the results brought no satisfying results
(data not shown), we scored the heterogeneity of the proteins,
which have yielded statistically significant correlations with either
clinicopathologic data and/or survival. The proteins included in the
cumulative tumor heterogeneity assessment were given as follows:
ESR1, PGR, PIK3CA, pAKT1, MYC, TOP2A, CDKN2A, RAD21,
and RUNX1. Thirty-nine (11.0%) patients were classified as
“globally heterogeneous”, with a score of at least 3. One hundred
forty-three (40.3%) patients were entirely homogenous, with a
score of 0. Cumulative tumor heterogeneity was compared with
clinicopathologic data and OS (Table 4 and Figure 2). It correlated
with higher stage, higher grade, non-endometrioid histology, and the
presence of metastases as well as shorter OS (all P b .05). Due to
multiple correlations among the studied parameters, only global
tumor heterogeneity, not the heterogeneity of separate proteins, was
included into the multivariate analysis. Cumulative heterogeneity
remained an independent prognostic factor, along with the stage and
tumor histology (Table 5).
Discussion
Intratumor heterogeneity is presumed to be the main reason based on
a single biopsy personalized treatment failure [2]. It can also disturbTable 4. Patients Classified as Globally Heterogeneous in the Context of Clinicopathologic Data
Number of Positive Samples P Value
Histology Endometrioid 31/323 (9.6%) .04
Non-endometrioid 6/27 (22.2%)
Stage I, II 24/291 (8.3%) .001
III, IV 13/59 (22.0%)
Grade 1, 2 24/300 (8.0%) .00003
3 13/44 (29.6%)
Metastases Absent 25/313 (8.3%) .00001
Present 11/33 (33.3%)
Figure 2. Kaplan-Meier curves representing the OS of EC patients stratified against the status of global tumor heterogeneity (P = .0008).
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emerging evidence suggests that the heterogeneity degree itself might
serve as a clinically valid molecular marker [22,23]. Although genetic
landscape of endometrial carcinoma has been extensively studied
[24], the protein heterogeneity in EC has received far less attention.
Analysis of the four cores collected from different regions of the
primary tumor provided evidence of protein heterogeneity in the
majority of the studied patients with EC. Thus, a single biopsy indeed
reveals only a small fraction of protein expression changes present in
an entire tumor.
Heterogeneity of tumors has been extensively studied in breast
cancer. Breast carcinomas were shown to possess allelic imbalance,
karyotypic diversity, and cell subpopulations of diverse therapy
sensitivity [25,26]. Furthermore, variable expression of ERBB2, cyclinTable 5. Univariate and Multivariate Analyses of Clinicopathologic Data and Global Tumor
Heterogeneity as Prognostic factors in EC Patients
Analyzed Parameter Univariate Analysis Multivariate Analysis
HR 95% CI P Value HR 95% CI P Value
Histology
(non-endometrioid vs
endometrioid)
4.36 2.61-7.29 .0000001 3.68 2.16-6.27 .000002
Stage (III, IV vs I, II) 1.97 1.62-2.39 .0000001 1.58 1.20-2.10 .001
Grade (3 vs 1, 2) 1.38 1.09-1.74 .008 Not significant
Metastases
(present vs absent)
3.60 2.23-5.81 .0000001 Not significant
Tumor heterogeneity
(present vs absent)
2.33 1.44-3.76 .0005 1.71 1.05-2.80 .03D1 (CCND1), MYC, and TOP2A has been reported within breast
tumors [27,28]. Triple negative breast carcinoma, known from its
aggressiveness and unfavorable prognosis, was characterized by explicit
intratumor genetic heterogeneity [29]. In non–small cell lung cancer,
ERBB1 amplification heterogeneity lowered targeted therapy efficiency
[30]. ERBB2 heterogeneity reported in endometrial and gastric cancers
was found to be the reason for discordant results with fluorescence in
situ hybridization [31,32]. Yoon et al. have demonstrated that
heterogeneous amplification of ERBB2 in esophageal adenocarcinoma
confers poor prognosis [33]. Studies of esophageal precancers revealed
that the degree of clonal diversity was found to increase the probability
of progression from esophageal precancer to adenocarcinoma [22].
Minor subpopulations of primary tumors were shown to be responsible
for relapse after drug administration [34]. Intratumor heterogeneity of
PTEN protein expression corresponded with loss of heterozygosity and
shorter OS in glioblastoma [35]. Tumor heterogeneity of Ki-67 protein
in prostate cancer correlated with more aggressive tumor characteristics
[5]. In this study, we have demonstrated that heterogeneity of
individual proteins, namely PIK3CA, MYC, TOP2A, ESR1, PGR,
RUNX1, RAD21, and CDKN2A, correlates with more aggressive
tumor behavior and, in case of MYC, TOP2A, ESR1, and RAD21,
also confers poor prognosis. Interestingly, prognostic significance
of the studied proteins depends on whether the heterogeneity or the
expression level is being analyzed. Apart from ESR1, PGR, and
TOP2A, which were significantly correlated with prognosis in terms of
both the heterogeneity and the expression level, there were also proteins
that were either informative in the context of tumor heterogeneity
(PIK3CA, MYC, CDKN2A, RAD21, and RUNX1) or protein
expression level (ERBB2, ERBB3, and TP53). Thus, protein
618 Protein Tumour Heterogeneity in Endometrial Cancer Supernat et al. Translational Oncology Vol. 7, No. 5, 2014heterogeneity and staining intensity might be two distinct phenomena,
differently reflecting the course of the disease.
Correlations between protein heterogeneity of ESR1 and
PGR, ESR1 and RAD21, and ERBB1 and pAKT1 were especially
strong. ESR1 and PGR1 expression was found to correlate strongly in
EC [36]. Investigation of ERBB1 and pAKT1 expression revealed
strong correlation between those two proteins in head and neck
squamous cell carcinoma [37]. Similarly, we have found statistically
significant correlations between ESR1 and PGR, ESR1 and RAD21,
and ERBB1 and pAKT1 (data not shown). Mentioned proteins are
functionally related. Perhaps if their expression is co-dependent, so
could be the heterogeneity.
Cumulative tumor heterogeneity of selected proteins’ heterogeneity
proved to be an independent predictor of survival and showed
the strongest correlations with clinicopathologic data. Apparently,
simultaneous analysis of a large number of protein markers gives more
thorough image of clonal diversity present in the tumor. Therefore,
we conclude that the larger the extent of intratumor heterogeneity in
EC, the more aggressive the tumor behavior is and thus the worse the
prognosis is.
One of the limitations of the study was relatively short follow-up period.
Furthermore, due to variable quality and sometimes small amount of
collected material, reliable analysis of all four cores per patient not always
could have been achieved. This issue was even greater in case of global
protein heterogeneity determination. However, despite TMA limitations,
there is an increasing number of publications based on tumor microarrays
due to their convenience. Even if performed analysis included four cores per
patient, which represents only a small proportion of the tumor studied, this
number still remains significant and gives deeper insight into tumor
composition than commonly used one core. Perhaps a method of Spiral
Array block generation would be of even better use for heterogeneity
determination [38]. Nevertheless, it was our study that indicated clearly the
heterogeneity of which proteins might be of use in EC.
Another problem was the lack of a unified system that would serve
accessing the heterogeneity within the studied markers. However, the
analyzed proteins have different functions within cells, which means
that they differ in terms of localization and quantity. Ergo, different
scoring criteria had to be assumed and unified evaluation and cutoff
determination were simply not feasible.
The studies concerning intratumor heterogeneity were primarily
performed at the genomic or transcriptomic level [2,39–41] and the
contribution of tumor diversity to disease progression has so far
received rather scarce attention. Nevertheless, effective cancer
treatment requires a complex idea about tumor structure and
intratumor heterogeneity needs to be taken into account [23]. To
the best of our knowledge, we are the first to present tumor
heterogeneity distribution measured by IHC in such a wide context.
We show that heterogeneity degree in EC might serve as a clinically
valid molecular marker and IHC could be a fast and simple method of
its determination.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.tranon.2014.06.001.
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